AKI Vs CKD Lecture Latest 3rd Dec 2018
AKI Vs CKD Lecture Latest 3rd Dec 2018
AKI Vs CKD Lecture Latest 3rd Dec 2018
• Glomerular
Intrinsic renal • Tubulo-interstitial
• Vascular (macro and micro)
Mehta R, Kellum J, Shah S, et al.: Acute kidney Injury Network: Report of an Initiative to improve outcomes in
Acute Kidney Injury. Critical Care 2007; 11: R31.
ETIOLOGY OF ACUTE KIDNEY INJURY
USE OF PPI TO PREVENT
ADVERSE EFFECT OF NSAID IN
PREVENTION OF PEPTIC ULCER
DISEASE MAYBE HARMFUL !
AVOIDING NSAID IS A RECOGNIZED METHOD OF
PREVENTING PROGRESSION OF CKD (CHRONIC
KIDNEY DISEASE)
RIFLE CLASSIFICATION
ADQI 2005
AKIN CLASSIFICATION
Coca S, Peixoto A, Garg A, et al.: The prognostic importance of a small acute decrement in kidney function in
hospitalized patients: a systematic review and meta-analysis. American Journal of Kidney Diseases 2007; 50:712-
720.
AKIN CLASSIFICATION
*Patients needing RRT are classified stage 3 despite the stage they were before starting RRT
Mehta R, Kellum J, Shah S, et al.: Acute kidney Injury Network: Report of an Initiative to improve outcomes in
Acute Kidney Injury. Critical Care 2007; 11: R31.
AKIN 2007
PATHOPHYSIOLOGY OF ACUTE KIDNEY INJURY:
ROLES OF POTENTIAL INHIBITORS OF INFLAMMATION
SPECTRUM OF KIDNEY INJURIES
AKI
CKD
MAINTAINING HEMODYNAMICS
AKI INITIAL CLINICAL ASSESSMENT
• In an unsteady state,
Creatinine does not accurately
reflect the GFR
KIM 1 Urine Intermediate Not tested Not tested Not tested none
2 12 1-3
hrs hrs days
Time
Insult
AKI Management
1. CRRT
CVVH, CVVHD, CVVHDF
2. SLEDD-f
3. SLEDD
4
POTENTIAL DRUGS TO AVOID DURING AKI
• NSAIDs
• ACEi, ARB
• Aminoglycosides
CONCLUSION
Both filtered by the glomerulus and secreted (10-15%) by the Filtered but not secreted by the kidney
proximal tubule
Dependant on age, sex, race and muscle mass Only determinants are age and sex, therefore more uniform
across populations
Can be affected by alterations in muscle mass and drugs that Not affected by muscle mass. May be influenced by thyroid
inhibit tubular secretion (cimetidine, trimethoprim) function and corticosteroid use
Inexpensive and easy to use Expensive, therefore will be reserved for confirmatory testing of
renal function
Used in estimation of CrCl and eGFR Incorporated into equations (CKD-EPI) estimating eGFR
Type of dialysis
HD and frequency, PD, CVVH
Drugs properties
Molecular weight, charge, water solubility, volume of distribution, dialyzer
membrane binding, non renal excretion pathway
Dialysis properties
Type of dialyser (pore size, surface area), flow rate/blood flow, dialysate
composition, volume of dialysate (PD), temperature, pH
Patient properties
Residual renal function, blood pressure, Kt/v
SUMMARY
• AKI and CKD management is a complex and dynamic clinical
management
• A reliable and stable biomarker should be considered for the
management especially in AKI setting
• Individualized treatment is required to ensure the accuracy and
safety clinical care to these patients
• AKI and CKD should not be seen as separate entity but as a
spectrum of a dynamic disease condition
• Dialysis modalities and concomitant drugs used should be reviewed
regularly
• Interaction between nephrologists and renal pharmacists is very
important to ensure the success of the management of these patients
SUMMARY
• AKI and CKD management is a complex and dynamic
clinical management
• Individualized treatment is required to ensure the accuracy
and safety clinical care to these patients
• AKI and CKD should not be seen as separate entity but as a
spectrum of a dynamic disease condition
• Dialysis modalities and concomitant drugs used should be
reviewed regularly
• Interaction between nephrologists and renal pharmacists is
very important to ensure the success of the management of
these patients